NASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis $1.21 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.23 +0.02 (+1.98%) As of 05/22/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pliant Therapeutics Stock (NASDAQ:PLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pliant Therapeutics alerts:Sign Up Key Stats Today's Range$1.20▼$1.2650-Day Range$1.15▼$1.3652-Week Range$1.09▼$1.95Volume212,117 shsAverage Volume437,533 shsMarket Capitalization$74.92 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingReduce Company Overview Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems. The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). In preclinical studies, Pliant has also advanced research-stage integrin modulators aimed at addressing fibrosis in diabetic nephropathy and other indications with high unmet medical need. Founded in 2015, Pliant has built its research and development capabilities around translational biomarkers and validated preclinical models. The company’s clinical programs are conducted through multi‐center studies in North America, with plans to expand patient enrollment into additional geographies as part of global development efforts. Leadership at Pliant is led by President and Chief Executive Officer Vikram Shembekar, who brings extensive biopharmaceutical development experience. The management team combines expertise in clinical development, regulatory strategy and commercialization planning, positioning the company to advance its integrin-targeted pipeline toward potential regulatory approvals and eventual patient access.AI Generated. May Contain Errors. Read More Pliant Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScorePLRX MarketRank™: Pliant Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 418th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingReduce Consensus RatingPliant Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 2 sell ratings.Upside PotentialPliant Therapeutics has a consensus price target of $3.00, representing about 147.9% upside from its current price of $1.21.Amount of Analyst CoveragePliant Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Pliant Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($1.37) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pliant Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pliant Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.92% of the float of Pliant Therapeutics has been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 5.33.Change versus previous monthShort interest in Pliant Therapeutics has recently decreased by 5.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.47 News SentimentPliant Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pliant Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.00% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLRX Stock News HeadlinesPliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 22, 2026 | seekingalpha.comPliant Therapeutics Announces Enrollment in Phase 1b Trial of PLN-101095 for ICI-Refractory Solid Tumors at ASCO 2026May 21, 2026 | quiverquant.comQOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown. | Behind the Markets (Ad)Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual MeetingMay 21, 2026 | globenewswire.comWall Street Zen Upgrades Pliant Therapeutics (NASDAQ:PLRX) to "Hold"May 19, 2026 | americanbankingnews.comPliant Therapeutics Stock Short Interest Report | NASDAQ:PLRX | BenzingaMay 17, 2026 | benzinga.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 11, 2026 | finance.yahoo.comPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 6, 2026 | globenewswire.comSee More Headlines PLRX Stock Analysis - Frequently Asked Questions How have PLRX shares performed this year? Pliant Therapeutics' stock was trading at $1.22 at the beginning of the year. Since then, PLRX stock has decreased by 0.8% and is now trading at $1.21. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04. When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $135 million in an IPO on Wednesday, June 3rd 2020. The company issued 9,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Top institutional investors of Pliant Therapeutics include ADAR1 Capital Management LLC (4.17%), Renaissance Technologies LLC (2.99%), Eversept Partners LP (1.44%) and Redmile Group LLC (1.25%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull, Mike Ouimette and Minnie Kuo. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings5/11/2026Today5/26/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PLRX's financial health is in the Yellow zone, according to TradeSmith. PLRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLRX CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees90Year Founded2016Price Target and Rating Average Price Target for Pliant Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+147.9%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.34 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.11% Return on Assets-44.37% Debt Debt-to-Equity RatioN/A Current Ratio16.89 Quick Ratio16.89 Sales & Book Value Annual Sales$1.58 million Price / Sales47.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book0.45Miscellaneous Outstanding Shares61,920,000Free Float56,966,000Market Cap$74.92 million OptionableOptionable Beta1.20 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:PLRX) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
